002622.Sz
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare services and equipment.
Business. The company operates in the healthcare sector, specializing in biotechnology and providing healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specializing in biotechnology and providing healthcare services and equipment.
The company's capital structure is characterized by a high debt-to-equity ratio of 1.67, indicating a significant reliance on debt financing. The liquidity position is assessed as medium, with a current ratio of 0.29, suggesting limited short-term liquidity to cover immediate liabilities. The price-to-book ratio of 8.13 indicates that the market values the company at a premium to its book value.
Profitability metrics show a negative return on equity of -0.4411 and a negative return on assets of -0.0879, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -125,610,940, and the net income is also negative at -119,422,450, reflecting poor operational performance.
The company's revenue is primarily concentrated in a single segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with the company's revenue streams.
The company's growth trajectory is uncertain, with no disclosed revenue growth or decline in the outlook. The operating cash flow is positive at 66,014,920, but the free cash flow is negative at -109,803,080, indicating that the company is not generating sufficient cash to fund its operations and capital expenditures.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity challenges. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics.
Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability.
- The company has a high debt-to-equity ratio, indicating a significant reliance on debt financing.
- The company is not generating returns for its shareholders or effectively utilizing its assets.
- The company's revenue is primarily concentrated in a single segment, increasing the risk associated with its revenue streams.
- The company's liquidity position is medium, with a current ratio of 0.29.
- The company's free cash flow is negative, indicating insufficient cash to fund operations and capital expenditures.
- **margin_outlook_rationale**: The company's negative operating income and net income suggest a decline in margins, driven by poor operational performance.
- **rd_outlook_rationale**: No specific information is available on the company's research and development activities or their impact on future performance.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 002622.SZ Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Biotechnologymedium
- Economic sector— → Healthcaremedium